<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37633753</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-108X</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Trends in neurosciences</Title><ISOAbbreviation>Trends Neurosci</ISOAbbreviation></Journal><ArticleTitle>Inflammasome assembly in neurodegenerative diseases.</ArticleTitle><Pagination><StartPage>814</StartPage><EndPage>831</EndPage><MedlinePgn>814-831</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tins.2023.07.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-2236(23)00174-1</ELocationID><Abstract><AbstractText>Neurodegenerative disorders are characterized by the progressive dysfunction and death of selectively vulnerable neuronal populations, often associated with the accumulation of aggregated host proteins. Sustained brain inflammation and hyperactivation of inflammasome complexes have been increasingly demonstrated to contribute to neurodegenerative disease progression. Here, we review molecular mechanisms leading to inflammasome assembly in neurodegeneration. We focus primarily on four degenerative brain disorders in which inflammasome hyperactivation has been well documented: Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), and the spectrum of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). We discuss shared and divergent principles of inflammasome assembly across these disorders, and underscore the differences between neurodegeneration-associated inflammasome activation pathways and their peripheral-immune counterparts. We examine how aberrant assembly of inflammasome complexes may amplify pathology in neurodegeneration, including misfolded protein aggregation, and highlight prospects for neurotherapeutic interventions based on targeting inflammasome pathways.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Jagjit</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Habean</LastName><ForeName>Maria L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Biomedical Scientist Training Program (Department of Neurosciences), Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panicker</LastName><ForeName>Nikhil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH 44106, USA; Kent State University, Neurosciences, School of Biomedical Sciences, Cleveland, OH, USA. Electronic address: PANICKN@ccf.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R00 AG066862</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trends Neurosci</MedlineTA><NlmUniqueID>7808616</NlmUniqueID><ISSNLinking>0166-2236</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058847" MajorTopicYN="N">Inflammasomes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AIM2</Keyword><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">NLRC4</Keyword><Keyword MajorTopicYN="N">NLRP1</Keyword><Keyword MajorTopicYN="N">NLRP3</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">multiple sclerosis</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>27</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>26</Day><Hour>21</Hour><Minute>58</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37633753</ArticleId><ArticleId IdType="mid">NIHMS1922690</ArticleId><ArticleId IdType="pmc">PMC10530301</ArticleId><ArticleId IdType="doi">10.1016/j.tins.2023.07.009</ArticleId><ArticleId IdType="pii">S0166-2236(23)00174-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hoffman HM et al. (2001) Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 29, 301&#x2013;305. 10.1038/ng756</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng756</ArticleId><ArticleId IdType="pmc">PMC4322000</ArticleId><ArticleId IdType="pubmed">11687797</ArticleId></ArticleIdList></Reference><Reference><Citation>Aganna E et al. (2002) Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 46, 2445&#x2013;2452. 10.1002/art.10509</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10509</ArticleId><ArticleId IdType="pubmed">12355493</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasula SM et al. (2002) The PYRIN-CARD protein ASC is an activating adaptor for caspase-1. J Biol Chem 277, 21119&#x2013;21122. 10.1074/jbc.C200179200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C200179200</ArticleId><ArticleId IdType="pubmed">11967258</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor W Jr. et al. (2003) Cutting edge: CIAS1/cryopyrin/PYPAF1/NALP3/CATERPILLER 1.1 is an inducible inflammatory mediator with NF-kappa B suppressive properties. J Immunol 171, 6329&#x2013;6333. 10.4049/jimmunol.171.12.6329</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.171.12.6329</ArticleId><ArticleId IdType="pubmed">14662828</ArticleId></ArticleIdList></Reference><Reference><Citation>Stehlik C et al. (2003) Apoptosis-associated speck-like protein containing a caspase recruitment domain is a regulator of procaspase-1 activation. J Immunol 171, 6154&#x2013;6163. 10.4049/jimmunol.171.11.6154</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.171.11.6154</ArticleId><ArticleId IdType="pubmed">14634131</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinon F et al. (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10, 417&#x2013;426. 10.1016/s1097-2765(02)00599-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1097-2765(02)00599-3</ArticleId><ArticleId IdType="pubmed">12191486</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariathasan S et al. (2004) Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430, 213&#x2013;218. 10.1038/nature02664</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02664</ArticleId><ArticleId IdType="pubmed">15190255</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutterwala FS et al. (2007) Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome. J Exp Med 204, 3235&#x2013;3245. 10.1084/jem.20071239</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20071239</ArticleId><ArticleId IdType="pmc">PMC2150987</ArticleId><ArticleId IdType="pubmed">18070936</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornung V et al. (2009) AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458, 514&#x2013;518. 10.1038/nature07725</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07725</ArticleId><ArticleId IdType="pmc">PMC2726264</ArticleId><ArticleId IdType="pubmed">19158675</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes-Alnemri T et al. (2009) AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458, 509&#x2013;513. 10.1038/nature07710</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07710</ArticleId><ArticleId IdType="pmc">PMC2862225</ArticleId><ArticleId IdType="pubmed">19158676</ArticleId></ArticleIdList></Reference><Reference><Citation>Burckstummer T et al. (2009) An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol 10, 266&#x2013;272. 10.1038/ni.1702</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1702</ArticleId><ArticleId IdType="pubmed">19158679</ArticleId></ArticleIdList></Reference><Reference><Citation>Miura M et al. (1993) Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell 75, 653&#x2013;660. 10.1016/0092-8674(93)90486-a</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(93)90486-a</ArticleId><ArticleId IdType="pubmed">8242741</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink SL and Cookson BT (2006) Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. Cell Microbiol 8, 1812&#x2013;1825. 10.1111/j.1462-5822.2006.00751.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1462-5822.2006.00751.x</ArticleId><ArticleId IdType="pubmed">16824040</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J et al. (2015) Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660&#x2013;665. 10.1038/nature15514</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature15514</ArticleId><ArticleId IdType="pubmed">26375003</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J et al. (2016) Pore-forming activity and structural autoinhibition of the gasdermin family. Nature 535, 111&#x2013;116. 10.1038/nature18590</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature18590</ArticleId><ArticleId IdType="pubmed">27281216</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko N et al. (2019) The role of interleukin-1 in general pathology. Inflamm Regen 39, 12. 10.1186/s41232-019-0101-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41232-019-0101-5</ArticleId><ArticleId IdType="pmc">PMC6551897</ArticleId><ArticleId IdType="pubmed">31182982</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugger BN and Dickson DW (2017) Pathology of Neurodegenerative Diseases. Cold Spring Harb Perspect Biol 9. 10.1101/cshperspect.a028035</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a028035</ArticleId><ArticleId IdType="pmc">PMC5495060</ArticleId><ArticleId IdType="pubmed">28062563</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass CK et al. (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918&#x2013;934. 10.1016/j.cell.2010.02.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.02.016</ArticleId><ArticleId IdType="pmc">PMC2873093</ArticleId><ArticleId IdType="pubmed">20303880</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon HS and Koh SH (2020) Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener 9, 42. 10.1186/s40035-020-00221-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-020-00221-2</ArticleId><ArticleId IdType="pmc">PMC7689983</ArticleId><ArticleId IdType="pubmed">33239064</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H (1994) Inflammatory response in Alzheimer&#x2019;s disease. Tohoku J Exp Med 174, 295&#x2013;303. 10.1620/tjem.174.295</Citation><ArticleIdList><ArticleId IdType="doi">10.1620/tjem.174.295</ArticleId><ArticleId IdType="pubmed">7539162</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL et al. (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson&#x2019;s and Alzheimer&#x2019;s disease brains. Neurology 38, 1285&#x2013;1291. 10.1212/wnl.38.8.1285</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.38.8.1285</ArticleId><ArticleId IdType="pubmed">3399080</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS et al. (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 86, 7611&#x2013;7615. 10.1073/pnas.86.19.7611</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.86.19.7611</ArticleId><ArticleId IdType="pmc">PMC298116</ArticleId><ArticleId IdType="pubmed">2529544</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagatsu T et al. (2000) Cytokines in Parkinson&#x2019;s disease. J Neural Transm Suppl, 143&#x2013;151</Citation><ArticleIdList><ArticleId IdType="pubmed">11128604</ArticleId></ArticleIdList></Reference><Reference><Citation>Bornemann KD et al. (2001) Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am J Pathol 158, 63&#x2013;73. 10.1016/s0002-9440(10)63945-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0002-9440(10)63945-4</ArticleId><ArticleId IdType="pmc">PMC1850262</ArticleId><ArticleId IdType="pubmed">11141480</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y et al. (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337&#x2013;351. 10.1016/j.neuron.2007.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.010</ArticleId><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicchetti F et al. (2002) Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 15, 991&#x2013;998. 10.1046/j.1460-9568.2002.01938.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1460-9568.2002.01938.x</ArticleId><ArticleId IdType="pubmed">11918659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A et al. (2007) Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson&#x2019;s disease. Proc Natl Acad Sci U S A 104, 18754&#x2013;18759. 10.1073/pnas.0704908104</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0704908104</ArticleId><ArticleId IdType="pmc">PMC2141849</ArticleId><ArticleId IdType="pubmed">18000063</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC et al. (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet 45, 1452&#x2013;1458. 10.1038/ng.2802</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2802</ArticleId><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Efthymiou AG and Goate AM (2017) Late onset Alzheimer&#x2019;s disease genetics implicates microglial pathways in disease risk. Mol Neurodegener 12, 43. 10.1186/s13024-017-0184-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0184-x</ArticleId><ArticleId IdType="pmc">PMC5446752</ArticleId><ArticleId IdType="pubmed">28549481</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogi M et al. (1996) Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson&#x2019;s disease. Neurosci Lett 211, 13&#x2013;16. 10.1016/0304-3940(96)12706-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(96)12706-3</ArticleId><ArticleId IdType="pubmed">8809836</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogi M (2000) Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain. J Neural Transm (Vienna) 107, 335&#x2013;341. 10.1007/s007020050028</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s007020050028</ArticleId><ArticleId IdType="pubmed">10821442</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacabelos R et al. (1994) Brain interleukin-1 beta in Alzheimer&#x2019;s disease and vascular dementia. Methods Find Exp Clin Pharmacol 16, 141&#x2013;151</Citation><ArticleIdList><ArticleId IdType="pubmed">8007743</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider H et al. (1998) A neuromodulatory role of interleukin-1beta in the hippocampus. Proc Natl Acad Sci U S A 95, 7778&#x2013;7783. 10.1073/pnas.95.13.7778</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.13.7778</ArticleId><ArticleId IdType="pmc">PMC22755</ArticleId><ArticleId IdType="pubmed">9636227</ArticleId></ArticleIdList></Reference><Reference><Citation>Yirmiya R et al. (2002) Brain interleukin-1 is involved in spatial memory and passive avoidance conditioning. Neurobiol Learn Mem 78, 379&#x2013;389. 10.1006/nlme.2002.4072</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nlme.2002.4072</ArticleId><ArticleId IdType="pubmed">12431424</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai SJ (2017) Effects of interleukin-1beta polymorphisms on brain function and behavior in healthy and psychiatric disease conditions. Cytokine Growth Factor Rev 37, 89&#x2013;97. 10.1016/j.cytogfr.2017.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2017.06.001</ArticleId><ArticleId IdType="pubmed">28599834</ArticleId></ArticleIdList></Reference><Reference><Citation>Halle A et al. (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9, 857&#x2013;865. 10.1038/ni.1636</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1636</ArticleId><ArticleId IdType="pmc">PMC3101478</ArticleId><ArticleId IdType="pubmed">18604209</ArticleId></ArticleIdList></Reference><Reference><Citation>James BD et al. (2014) Contribution of Alzheimer disease to mortality in the United States. Neurology 82, 1045&#x2013;1050. 10.1212/WNL.0000000000000240</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000240</ArticleId><ArticleId IdType="pmc">PMC3962992</ArticleId><ArticleId IdType="pubmed">24598707</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelenboom P and Veerhuis R (1996) The role of complement and activated microglia in the pathogenesis of Alzheimer&#x2019;s disease. Neurobiol Aging 17, 673&#x2013;680. 10.1016/0197-4580(96)00108-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(96)00108-x</ArticleId><ArticleId IdType="pubmed">8892339</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjoneska E et al. (2015) Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer&#x2019;s disease. Nature 518, 365&#x2013;369. 10.1038/nature14252</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14252</ArticleId><ArticleId IdType="pmc">PMC4530583</ArticleId><ArticleId IdType="pubmed">25693568</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT et al. (2013) NLRP3 is activated in Alzheimer&#x2019;s disease and contributes to pathology in APP/PS1 mice. Nature 493, 674&#x2013;678. 10.1038/nature11729</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11729</ArticleId><ArticleId IdType="pmc">PMC3812809</ArticleId><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Dempsey C et al. (2017) Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-beta and cognitive function in APP/PS1 mice. Brain Behav Immun 61, 306&#x2013;316. 10.1016/j.bbi.2016.12.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2016.12.014</ArticleId><ArticleId IdType="pubmed">28003153</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores J et al. (2018) Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer&#x2019;s disease mouse model. Nat Commun 9, 3916. 10.1038/s41467-018-06449-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06449-x</ArticleId><ArticleId IdType="pmc">PMC6156230</ArticleId><ArticleId IdType="pubmed">30254377</ArticleId></ArticleIdList></Reference><Reference><Citation>Luciunaite A et al. (2020) Soluble Abeta oligomers and protofibrils induce NLRP3 inflammasome activation in microglia. J Neurochem 155, 650&#x2013;661. 10.1111/jnc.14945</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14945</ArticleId><ArticleId IdType="pubmed">31872431</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S et al. (2023) Role of the caspase-8/RIPK3 axis in Alzheimer&#x2019;s disease pathogenesis and Abeta-induced NLRP3 inflammasome activation. JCI Insight 8. 10.1172/jci.insight.157433</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.157433</ArticleId><ArticleId IdType="pmc">PMC9977425</ArticleId><ArticleId IdType="pubmed">36602874</ArticleId></ArticleIdList></Reference><Reference><Citation>Aman Y et al. (2021) Autophagy in healthy aging and disease. Nat Aging 1, 634&#x2013;650. 10.1038/s43587-021-00098-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43587-021-00098-4</ArticleId><ArticleId IdType="pmc">PMC8659158</ArticleId><ArticleId IdType="pubmed">34901876</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho MH et al. (2014) Autophagy in microglia degrades extracellular beta-amyloid fibrils and regulates the NLRP3 inflammasome. Autophagy 10, 1761&#x2013;1775. 10.4161/auto.29647</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.29647</ArticleId><ArticleId IdType="pmc">PMC4198361</ArticleId><ArticleId IdType="pubmed">25126727</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi CS (2012) Activation of autophagy by inflammatory signals limits IL-1beta production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol 13, 255&#x2013;263. 10.1038/ni.2215</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2215</ArticleId><ArticleId IdType="pmc">PMC4116819</ArticleId><ArticleId IdType="pubmed">22286270</ArticleId></ArticleIdList></Reference><Reference><Citation>Houtman J et al. (2019) Beclin1-driven autophagy modulates the inflammatory response of microglia via NLRP3. EMBO J 38. 10.15252/embj.201899430</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201899430</ArticleId><ArticleId IdType="pmc">PMC6376276</ArticleId><ArticleId IdType="pubmed">30617086</ArticleId></ArticleIdList></Reference><Reference><Citation>Heckmann BL et al. (2019) LC3-Associated Endocytosis Facilitates beta-Amyloid Clearance and Mitigates Neurodegeneration in Murine Alzheimer&#x2019;s Disease. Cell 178, 536&#x2013;551 e514. 10.1016/j.cell.2019.05.056</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.05.056</ArticleId><ArticleId IdType="pmc">PMC6689199</ArticleId><ArticleId IdType="pubmed">31257024</ArticleId></ArticleIdList></Reference><Reference><Citation>Heckmann BL et al. (2020) Noncanonical function of an autophagy protein prevents spontaneous Alzheimer&#x2019;s disease. Sci Adv 6, eabb9036. 10.1126/sciadv.abb9036</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abb9036</ArticleId><ArticleId IdType="pmc">PMC7428329</ArticleId><ArticleId IdType="pubmed">32851186</ArticleId></ArticleIdList></Reference><Reference><Citation>Kummer MP et al. (2021) Microglial PD-1 stimulation by astrocytic PD-L1 suppresses neuroinflammation and Alzheimer&#x2019;s disease pathology. EMBO J 40, e108662. 10.15252/embj.2021108662</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2021108662</ArticleId><ArticleId IdType="pmc">PMC8672180</ArticleId><ArticleId IdType="pubmed">34825707</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutz A et al. (2017) NLRP3 inflammasome assembly is regulated by phosphorylation of the pyrin domain. J Exp Med 214, 1725&#x2013;1736. 10.1084/jem.20160933</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20160933</ArticleId><ArticleId IdType="pmc">PMC5460996</ArticleId><ArticleId IdType="pubmed">28465465</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y et al. (2018) TREM2 Is a Receptor for beta-Amyloid that Mediates Microglial Function. Neuron 97, 1023&#x2013;1031 e1027. 10.1016/j.neuron.2018.01.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.01.031</ArticleId><ArticleId IdType="pmc">PMC5889092</ArticleId><ArticleId IdType="pubmed">29518356</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosker K et al. (2021) Microglial signalling pathway deficits associated with the patient derived R47H TREM2 variants linked to AD indicate inability to activate inflammasome. Sci Rep 11, 13316. 10.1038/s41598-021-91207-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-91207-1</ArticleId><ArticleId IdType="pmc">PMC8233372</ArticleId><ArticleId IdType="pubmed">34172778</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S et al. (2017) The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47, 566&#x2013;581 e569. 10.1016/j.immuni.2017.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.08.008</ArticleId><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N et al. (2022) Elevating microglia TREM2 reduces amyloid seeding and suppresses disease-associated microglia. J Exp Med 219. 10.1084/jem.20212479</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20212479</ArticleId><ArticleId IdType="pmc">PMC9481739</ArticleId><ArticleId IdType="pubmed">36107206</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoch KM et al. (2021) Acute Trem2 reduction triggers increased microglial phagocytosis, slowing amyloid deposition in mice. Proc Natl Acad Sci U S A 118. 10.1073/pnas.2100356118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2100356118</ArticleId><ArticleId IdType="pmc">PMC8271763</ArticleId><ArticleId IdType="pubmed">34187891</ArticleId></ArticleIdList></Reference><Reference><Citation>Meilandt WJ et al. (2020) Trem2 Deletion Reduces Late-Stage Amyloid Plaque Accumulation, Elevates the Abeta42:Abeta40 Ratio, and Exacerbates Axonal Dystrophy and Dendritic Spine Loss in the PS2APP Alzheimer&#x2019;s Mouse Model. J Neurosci 40, 1956&#x2013;1974. 10.1523/JNEUROSCI.1871-19.2019</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1871-19.2019</ArticleId><ArticleId IdType="pmc">PMC7046459</ArticleId><ArticleId IdType="pubmed">31980586</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasrabady SE et al. (2018) White matter changes in Alzheimer&#x2019;s disease: a focus on myelin and oligodendrocytes. Acta Neuropathol Commun 6, 22. 10.1186/s40478-018-0515-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0515-3</ArticleId><ArticleId IdType="pmc">PMC5834839</ArticleId><ArticleId IdType="pubmed">29499767</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X et al. (2020) Oligodendroglial glycolytic stress triggers inflammasome activation and neuropathology in Alzheimer&#x2019;s disease. Sci Adv 6. 10.1126/sciadv.abb8680</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abb8680</ArticleId><ArticleId IdType="pmc">PMC7717916</ArticleId><ArticleId IdType="pubmed">33277246</ArticleId></ArticleIdList></Reference><Reference><Citation>Saresella M et al. (2016) The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer&#x2019;s disease. Mol Neurodegener 11, 23. 10.1186/s13024-016-0088-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0088-1</ArticleId><ArticleId IdType="pmc">PMC4778358</ArticleId><ArticleId IdType="pubmed">26939933</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejera D (2019) Systemic inflammation impairs microglial Abeta clearance through NLRP3 inflammasome. EMBO J 38, e101064. 10.15252/embj.2018101064</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2018101064</ArticleId><ArticleId IdType="pmc">PMC6717897</ArticleId><ArticleId IdType="pubmed">31359456</ArticleId></ArticleIdList></Reference><Reference><Citation>Stancu IC et al. (2019) Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo. Acta Neuropathol 137, 599&#x2013;617. 10.1007/s00401-018-01957-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-01957-y</ArticleId><ArticleId IdType="pmc">PMC6426830</ArticleId><ArticleId IdType="pubmed">30721409</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S et al. (2021) Proteopathic tau primes and activates interleukin-1beta via myeloid-cell-specific MyD88- and NLRP3-ASC-inflammasome pathway. Cell Rep 36, 109720. 10.1016/j.celrep.2021.109720</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109720</ArticleId><ArticleId IdType="pmc">PMC8491766</ArticleId><ArticleId IdType="pubmed">34551296</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan MS et al. (2014) Amyloid-beta induces NLRP1-dependent neuronal pyroptosis in models of Alzheimer&#x2019;s disease. Cell Death Dis 5, e1382. 10.1038/cddis.2014.348</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2014.348</ArticleId><ArticleId IdType="pmc">PMC4454321</ArticleId><ArticleId IdType="pubmed">25144717</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushal V et al. (2015) Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated Caspase-6 activation. Cell Death Differ 22, 1676&#x2013;1686. 10.1038/cdd.2015.16</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2015.16</ArticleId><ArticleId IdType="pmc">PMC4563782</ArticleId><ArticleId IdType="pubmed">25744023</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammert CR et al. (2020) AIM2 inflammasome surveillance of DNA damage shapes neurodevelopment. Nature 580, 647&#x2013;652. 10.1038/s41586-020-2174-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2174-3</ArticleId><ArticleId IdType="pmc">PMC7788527</ArticleId><ArticleId IdType="pubmed">32350463</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu PJ et al. (2017) Deletion of the Inflammasome Sensor Aim2 Mitigates Abeta Deposition and Microglial Activation but Increases Inflammatory Cytokine Expression in an Alzheimer Disease Mouse Model. Neuroimmunomodulation 24, 29&#x2013;39. 10.1159/000477092</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000477092</ArticleId><ArticleId IdType="pubmed">28618410</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaborators GBDN (2019) Global, regional, and national burden of neurological disorders, 1990&#x2013;2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18, 459&#x2013;480. 10.1016/S1474-4422(18)30499-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30499-X</ArticleId><ArticleId IdType="pmc">PMC6459001</ArticleId><ArticleId IdType="pubmed">30879893</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorsey ER et al. (2018) The Emerging Evidence of the Parkinson Pandemic. J Parkinsons Dis 8, S3&#x2013;S8. 10.3233/JPD-181474</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-181474</ArticleId><ArticleId IdType="pmc">PMC6311367</ArticleId><ArticleId IdType="pubmed">30584159</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H et al. (2003) Staging of brain pathology related to sporadic Parkinson&#x2019;s disease. Neurobiol Aging 24, 197&#x2013;211. 10.1016/s0197-4580(02)00065-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0197-4580(02)00065-9</ArticleId><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H et al. (2002) Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson&#x2019;s disease (preclinical and clinical stages). J Neurol 249 Suppl 3, III/1&#x2013;5. 10.1007/s00415-002-1301-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-002-1301-4</ArticleId><ArticleId IdType="pubmed">12528692</ArticleId></ArticleIdList></Reference><Reference><Citation>Tansey MG et al. (2022) Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol 22, 657&#x2013;673. 10.1038/s41577-022-00684-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00684-6</ArticleId><ArticleId IdType="pmc">PMC8895080</ArticleId><ArticleId IdType="pubmed">35246670</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen Reish HE and Standaert DG (2015) Role of alpha-synuclein in inducing innate and adaptive immunity in Parkinson disease. J Parkinsons Dis 5, 1&#x2013;19. 10.3233/JPD-140491</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-140491</ArticleId><ArticleId IdType="pmc">PMC4405142</ArticleId><ArticleId IdType="pubmed">25588354</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon R et al. (2018) Inflammasome inhibition prevents alpha-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med 10. 10.1126/scitranslmed.aah4066</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aah4066</ArticleId><ArticleId IdType="pmc">PMC6483075</ArticleId><ArticleId IdType="pubmed">30381407</ArticleId></ArticleIdList></Reference><Reference><Citation>Panicker N et al. (2019) Fyn kinase regulates misfolded alpha-synuclein uptake and NLRP3 inflammasome activation in microglia. J Exp Med 216, 1411&#x2013;1430. 10.1084/jem.20182191</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20182191</ArticleId><ArticleId IdType="pmc">PMC6547864</ArticleId><ArticleId IdType="pubmed">31036561</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Y (2015) Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell 160, 62&#x2013;73. 10.1016/j.cell.2014.11.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.11.047</ArticleId><ArticleId IdType="pubmed">25594175</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike AF et al. (2022) Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson&#x2019;s disease. J Neuroinflammation 19, 50. 10.1186/s12974022-02410-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974022-02410-4</ArticleId><ArticleId IdType="pmc">PMC8848816</ArticleId><ArticleId IdType="pubmed">35172843</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon HE and Paek SH (2015) Mitochondrial Dysfunction in Parkinson&#x2019;s Disease. Exp Neurobiol 24, 103&#x2013;116. 10.5607/en.2015.24.2.103</Citation><ArticleIdList><ArticleId IdType="doi">10.5607/en.2015.24.2.103</ArticleId><ArticleId IdType="pmc">PMC4479806</ArticleId><ArticleId IdType="pubmed">26113789</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou R et al. (2011) A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221&#x2013;225. 10.1038/nature09663</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09663</ArticleId><ArticleId IdType="pubmed">21124315</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar S et al. (2017) Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson&#x2019;s disease. NPJ Parkinsons Dis 3, 30. 10.1038/s41531-017-0032-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-017-0032-2</ArticleId><ArticleId IdType="pmc">PMC5645400</ArticleId><ArticleId IdType="pubmed">29057315</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C et al. (2013) Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun 4, 1562. 10.1038/ncomms2534</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2534</ArticleId><ArticleId IdType="pmc">PMC4089961</ArticleId><ArticleId IdType="pubmed">23463005</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniele SG et al. (2015) Activation of MyD88-dependent TLR1/2 signaling by misfolded alpha-synuclein, a protein linked to neurodegenerative disorders. Sci Signal 8, ra45. 10.1126/scisignal.2005965</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.2005965</ArticleId><ArticleId IdType="pmc">PMC4601639</ArticleId><ArticleId IdType="pubmed">25969543</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S et al. (2015) alpha-Synuclein, a chemoattractant, directs microglial migration via H2O2-dependent Lyn phosphorylation. Proc Natl Acad Sci U S A 112, E1926&#x2013;1935. 10.1073/pnas.1417883112</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1417883112</ArticleId><ArticleId IdType="pmc">PMC4403145</ArticleId><ArticleId IdType="pubmed">25825709</ArticleId></ArticleIdList></Reference><Reference><Citation>Long H et al. (2022) Interaction of RAGE with alpha-synuclein fibrils mediates inflammatory response of microglia. Cell Rep 40, 111401. 10.1016/j.celrep.2022.111401</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111401</ArticleId><ArticleId IdType="pubmed">36130498</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheiblich H et al. (2021) Microglial NLRP3 Inflammasome Activation upon TLR2 and TLR5 Ligation by Distinct alpha-Synuclein Assemblies. J Immunol 207, 2143&#x2013;2154. 10.4049/jimmunol.2100035</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2100035</ArticleId><ArticleId IdType="pmc">PMC8490941</ArticleId><ArticleId IdType="pubmed">34507948</ArticleId></ArticleIdList></Reference><Reference><Citation>Szego EM et al. (2022) Constitutively active STING causes neuroinflammation and degeneration of dopaminergic neurons in mice. Elife 11. 10.7554/eLife.81943</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.81943</ArticleId><ArticleId IdType="pmc">PMC9767458</ArticleId><ArticleId IdType="pubmed">36314770</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinkle JT et al. (2022) STING mediates neurodegeneration and neuroinflammation in nigrostriatal alpha-synucleinopathy. Proc Natl Acad Sci U S A 119, e2118819119. 10.1073/pnas.2118819119</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2118819119</ArticleId><ArticleId IdType="pmc">PMC9169780</ArticleId><ArticleId IdType="pubmed">35394877</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon OC et al. (2021) SGK1 inhibition in glia ameliorates pathologies and symptoms in Parkinson disease animal models. EMBO Mol Med 13, e13076. 10.15252/emmm.202013076</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202013076</ArticleId><ArticleId IdType="pmc">PMC8033538</ArticleId><ArticleId IdType="pubmed">33646633</ArticleId></ArticleIdList></Reference><Reference><Citation>Panicker N et al. (2022) Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinson&#x2019;s disease. Neuron 110, 2422&#x2013;2437 e2429. 10.1016/j.neuron.2022.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2022.05.009</ArticleId><ArticleId IdType="pmc">PMC9357148</ArticleId><ArticleId IdType="pubmed">35654037</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan YQ et al. (2023) Parkin regulates microglial NLRP3 and represses neurodegeneration in Parkinson&#x2019;s disease. Aging Cell, e13834. 10.1111/acel.13834</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.13834</ArticleId><ArticleId IdType="pmc">PMC10265164</ArticleId><ArticleId IdType="pubmed">37029500</ArticleId></ArticleIdList></Reference><Reference><Citation>Rui WJ et al. (2022) Microglial AIM2 alleviates antiviral-related neuro-inflammation in mouse models of Parkinson&#x2019;s disease. Glia 70, 2409&#x2013;2425. 10.1002/glia.24260</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.24260</ArticleId><ArticleId IdType="pubmed">35959803</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W et al. (2016) Caspase-1 causes truncation and aggregation of the Parkinson&#x2019;s disease-associated protein alpha-synuclein. Proc Natl Acad Sci U S A 113, 9587&#x2013;9592. 10.1073/pnas.1610099113</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1610099113</ArticleId><ArticleId IdType="pmc">PMC5003239</ArticleId><ArticleId IdType="pubmed">27482083</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P et al. (2016) Cdk5-Dependent Activation of Neuronal Inflammasomes in Parkinson&#x2019;s Disease. Mov Disord 31, 366&#x2013;376. 10.1002/mds.26488</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26488</ArticleId><ArticleId IdType="pubmed">26853432</ArticleId></ArticleIdList></Reference><Reference><Citation>von Herrmann KM et al. (2018) NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson&#x2019;s disease. NPJ Parkinsons Dis 4, 24. 10.1038/s41531-018-0061-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-018-0061-5</ArticleId><ArticleId IdType="pmc">PMC6093937</ArticleId><ArticleId IdType="pubmed">30131971</ArticleId></ArticleIdList></Reference><Reference><Citation>Noseworthy JH et al. (2000) Multiple sclerosis. N Engl J Med 343, 938&#x2013;952. 10.1056/NEJM200009283431307</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200009283431307</ArticleId><ArticleId IdType="pubmed">11006371</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapp BD et al. (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338, 278&#x2013;285. 10.1056/NEJM199801293380502</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199801293380502</ArticleId><ArticleId IdType="pubmed">9445407</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinley MP et al. (2021) Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA 325, 765&#x2013;779. 10.1001/jama.2020.26858</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.26858</ArticleId><ArticleId IdType="pubmed">33620411</ArticleId></ArticleIdList></Reference><Reference><Citation>Constantinescu CS et al. (2011) Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol 164, 1079&#x2013;1106. 10.1111/j.1476-5381.2011.01302.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.2011.01302.x</ArticleId><ArticleId IdType="pmc">PMC3229753</ArticleId><ArticleId IdType="pubmed">21371012</ArticleId></ArticleIdList></Reference><Reference><Citation>Torkildsen O et al. (2008) The cuprizone model for demyelination. Acta Neurol Scand Suppl 188, 72&#x2013;76. 10.1111/j.1600-0404.2008.01036.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2008.01036.x</ArticleId><ArticleId IdType="pubmed">18439226</ArticleId></ArticleIdList></Reference><Reference><Citation>Furlan R et al. (1999) Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol 163, 2403&#x2013;2409</Citation><ArticleIdList><ArticleId IdType="pubmed">10452974</ArticleId></ArticleIdList></Reference><Reference><Citation>Gris D et al. (2010) NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J Immunol 185, 974&#x2013;981. 10.4049/jimmunol.0904145</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0904145</ArticleId><ArticleId IdType="pmc">PMC3593010</ArticleId><ArticleId IdType="pubmed">20574004</ArticleId></ArticleIdList></Reference><Reference><Citation>Jha S et al. (2010) The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18. J Neurosci 30, 15811&#x2013;15820. 10.1523/JNEUROSCI.4088-10.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4088-10.2010</ArticleId><ArticleId IdType="pmc">PMC6633756</ArticleId><ArticleId IdType="pubmed">21106820</ArticleId></ArticleIdList></Reference><Reference><Citation>Voet S et al. (2018) A20 critically controls microglia activation and inhibits inflammasome-dependent neuroinflammation. Nat Commun 9, 2036. 10.1038/s41467-018-04376-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-04376-5</ArticleId><ArticleId IdType="pmc">PMC5964249</ArticleId><ArticleId IdType="pubmed">29789522</ArticleId></ArticleIdList></Reference><Reference><Citation>Farooqui AA et al. (2006) Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev 58, 591&#x2013;620. 10.1124/pr.58.3.7</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.58.3.7</ArticleId><ArticleId IdType="pubmed">16968951</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman L et al. (2017) NLR members NLRC4 and NLRP3 mediate sterile inflammasome activation in microglia and astrocytes. J Exp Med 214, 1351&#x2013;1370. 10.1084/jem.20150237</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20150237</ArticleId><ArticleId IdType="pmc">PMC5413320</ArticleId><ArticleId IdType="pubmed">28404595</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang CJ et al. (2018) TLR-stimulated IRAKM activates caspase-8 inflammasome in microglia and promotes neuroinflammation. J Clin Invest 128, 5399&#x2013;5412. 10.1172/JCI121901</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI121901</ArticleId><ArticleId IdType="pmc">PMC6264724</ArticleId><ArticleId IdType="pubmed">30372424</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland DW and Rothstein JD (2001) From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2, 806&#x2013;819. 10.1038/35097565</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35097565</ArticleId><ArticleId IdType="pubmed">11715057</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM (2006) Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. Curr Neurol Neurosci Rep 6, 37&#x2013;46. 10.1007/s11910-996-0008-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-996-0008-9</ArticleId><ArticleId IdType="pubmed">16469270</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedlander RM et al. (1997) Inhibition of ICE slows ALS in mice. Nature 388, 31. 10.1038/40299</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/40299</ArticleId><ArticleId IdType="pubmed">9214497</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M et al. (2009) Variation in aggregation propensities among ALS-associated variants of SOD1: correlation to human disease. Hum Mol Genet 18, 3217&#x2013;3226. 10.1093/hmg/ddp260</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp260</ArticleId><ArticleId IdType="pmc">PMC2722984</ArticleId><ArticleId IdType="pubmed">19483195</ArticleId></ArticleIdList></Reference><Reference><Citation>Meissner F et al. (2010) Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proc Natl Acad Sci U S A 107, 13046&#x2013;13050. 10.1073/pnas.1002396107</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1002396107</ArticleId><ArticleId IdType="pmc">PMC2919927</ArticleId><ArticleId IdType="pubmed">20616033</ArticleId></ArticleIdList></Reference><Reference><Citation>Deora V et al. (2020) The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins. Glia 68, 407&#x2013;421. 10.1002/glia.23728</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23728</ArticleId><ArticleId IdType="pubmed">31596526</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS et al. (2009) TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem 284, 20329&#x2013;20339. 10.1074/jbc.M109.010264</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.010264</ArticleId><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W et al. (2015) TDP-43 activates microglia through NF-kappaB and NLRP3 inflammasome. Exp Neurol 273, 24&#x2013;35. 10.1016/j.expneurol.2015.07.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2015.07.019</ArticleId><ArticleId IdType="pubmed">26222336</ArticleId></ArticleIdList></Reference><Reference><Citation>Bang J et al. (2015) Frontotemporal dementia. Lancet 386, 1672&#x2013;1682. 10.1016/S0140-6736(15)00461-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)00461-4</ArticleId><ArticleId IdType="pmc">PMC5970949</ArticleId><ArticleId IdType="pubmed">26595641</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramzon YA et al. (2020) The Overlapping Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Front Neurosci 14, 42. 10.3389/fnins.2020.00042</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00042</ArticleId><ArticleId IdType="pmc">PMC7012787</ArticleId><ArticleId IdType="pubmed">32116499</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M et al. (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256. 10.1016/j.neuron.2011.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X et al. (2014) Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron 84, 1213&#x2013;1225. 10.1016/j.neuron.2014.12.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.12.010</ArticleId><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu RH et al. (2022) C9-ALS-Associated Proline-Arginine Dipeptide Repeat Protein Induces Activation of NLRP3 Inflammasome of HMC3 Microglia Cells by Binding of Complement Component 1 Q Subcomponent-Binding Protein (C1QBP), and Syringin Prevents This Effect. Cells 11. 10.3390/cells11193128</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11193128</ArticleId><ArticleId IdType="pmc">PMC9563448</ArticleId><ArticleId IdType="pubmed">36231090</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu X et al. (2023) Negative regulation of TREM2-mediated C9orf72 poly-GA clearance by the NLRP3 inflammasome. Cell Rep 42, 112133. 10.1016/j.celrep.2023.112133</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.112133</ArticleId><ArticleId IdType="pubmed">36800288</ArticleId></ArticleIdList></Reference><Reference><Citation>Vince JE et al. (2018) The Mitochondrial Apoptotic Effectors BAX/BAK Activate Caspase-3 and &#x2212;7 to Trigger NLRP3 Inflammasome and Caspase-8 Driven IL-1beta Activation. Cell Rep 25, 2339&#x2013;2353 e2334. 10.1016/j.celrep.2018.10.103</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.10.103</ArticleId><ArticleId IdType="pubmed">30485804</ArticleId></ArticleIdList></Reference><Reference><Citation>Degterev A et al. (2005) Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 1, 112&#x2013;119. 10.1038/nchembio711</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio711</ArticleId><ArticleId IdType="pubmed">16408008</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J et al. (2019) Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nat Rev Neurosci 20, 19&#x2013;33. 10.1038/s41583-018-0093-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-018-0093-1</ArticleId><ArticleId IdType="pmc">PMC6342007</ArticleId><ArticleId IdType="pubmed">30467385</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang TB et al. (2013) Caspase-8 blocks kinase RIPK3-mediated activation of the NLRP3 inflammasome. Immunity 38, 27&#x2013;40. 10.1016/j.immuni.2012.09.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2012.09.015</ArticleId><ArticleId IdType="pubmed">23260196</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawlor KE et al. (2015) RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL. Nat Commun 6, 6282. 10.1038/ncomms7282</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7282</ArticleId><ArticleId IdType="pmc">PMC4346630</ArticleId><ArticleId IdType="pubmed">25693118</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez KD et al. (2017) MLKL Activation Triggers NLRP3-Mediated Processing and Release of IL-1beta Independently of Gasdermin-D. J Immunol 198, 2156&#x2013;2164. 10.4049/jimmunol.1601757</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1601757</ArticleId><ArticleId IdType="pmc">PMC5321867</ArticleId><ArticleId IdType="pubmed">28130493</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y et al. (2016) RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science 353, 603&#x2013;608. 10.1126/science.aaf6803</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf6803</ArticleId><ArticleId IdType="pmc">PMC5444917</ArticleId><ArticleId IdType="pubmed">27493188</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SH et al. (2017) Nec-1 alleviates cognitive impairment with reduction of Abeta and tau abnormalities in APP/PS1 mice. EMBO Mol Med 9, 61&#x2013;77. 10.15252/emmm.201606566</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606566</ArticleId><ArticleId IdType="pmc">PMC5210088</ArticleId><ArticleId IdType="pubmed">27861127</ArticleId></ArticleIdList></Reference><Reference><Citation>Re DB et al. (2014) Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron 81, 1001&#x2013;1008. 10.1016/j.neuron.2014.01.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.01.011</ArticleId><ArticleId IdType="pmc">PMC3951532</ArticleId><ArticleId IdType="pubmed">24508385</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofengeim D et al. (2017) RIPK1 mediates a disease-associated microglial response in Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A 114, E8788&#x2013;E8797. 10.1073/pnas.1714175114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1714175114</ArticleId><ArticleId IdType="pmc">PMC5642727</ArticleId><ArticleId IdType="pubmed">28904096</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG et al. (1996) In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging 17, 761&#x2013;766. 10.1016/0197-4580(96)00104-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(96)00104-2</ArticleId><ArticleId IdType="pmc">PMC3886636</ArticleId><ArticleId IdType="pubmed">8892349</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft JM et al. (2005) Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human beta-amyloid. J Neuroinflammation 2, 15. 10.1186/1742-2094-2-15</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-2-15</ArticleId><ArticleId IdType="pmc">PMC1190207</ArticleId><ArticleId IdType="pubmed">15967035</ArticleId></ArticleIdList></Reference><Reference><Citation>Das P et al. (2006) Interleukin-1 receptor 1 knockout has no effect on amyloid deposition in Tg2576 mice and does not alter efficacy following Abeta immunotherapy. J Neuroinflammation 3, 17. 10.1186/1742-2094-3-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-3-17</ArticleId><ArticleId IdType="pmc">PMC1559596</ArticleId><ArticleId IdType="pubmed">16872492</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaftel SS et al. (2007) Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 117, 1595&#x2013;1604. 10.1172/JCI31450</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI31450</ArticleId><ArticleId IdType="pmc">PMC1878531</ArticleId><ArticleId IdType="pubmed">17549256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh S et al. (2013) Sustained interleukin-1beta overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer&#x2019;s mouse model. J Neurosci 33, 5053&#x2013;5064. 10.1523/JNEUROSCI.4361-12.2013</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4361-12.2013</ArticleId><ArticleId IdType="pmc">PMC3637949</ArticleId><ArticleId IdType="pubmed">23486975</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzeng TC et al. (2018) Inflammasome-derived cytokine IL18 suppresses amyloid-induced seizures in Alzheimer-prone mice. Proc Natl Acad Sci U S A 115, 9002&#x2013;9007. 10.1073/pnas.1801802115</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1801802115</ArticleId><ArticleId IdType="pmc">PMC6130368</ArticleId><ArticleId IdType="pubmed">30127003</ArticleId></ArticleIdList></Reference><Reference><Citation>Pott Godoy MC et al. (2008) Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson&#x2019;s disease. Brain 131, 1880&#x2013;1894. 10.1093/brain/awn101</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn101</ArticleId><ArticleId IdType="pmc">PMC2442423</ArticleId><ArticleId IdType="pubmed">18504291</ArticleId></ArticleIdList></Reference><Reference><Citation>Stojakovic A et al. (2017) Role of the IL-1 Pathway in Dopaminergic Neurodegeneration and Decreased Voluntary Movement. Mol Neurobiol 54, 4486&#x2013;4495. 10.1007/s12035-016-9988-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-9988-x</ArticleId><ArticleId IdType="pmc">PMC5509814</ArticleId><ArticleId IdType="pubmed">27356916</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS et al. (2006) Interleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflammation 3, 5. 10.1186/1742-2094-3-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-3-5</ArticleId><ArticleId IdType="pmc">PMC1435743</ArticleId><ArticleId IdType="pubmed">16542445</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue M et al. (2012) NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 109, 10480&#x2013;10485. 10.1073/pnas.1201836109</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1201836109</ArticleId><ArticleId IdType="pmc">PMC3387125</ArticleId><ArticleId IdType="pubmed">22699511</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S et al. (2019) Gasdermin D in peripheral myeloid cells drives neuroinflammation in experimental autoimmune encephalomyelitis. J Exp Med 216, 2562&#x2013;2581. 10.1084/jem.20190377</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20190377</ArticleId><ArticleId IdType="pmc">PMC6829591</ArticleId><ArticleId IdType="pubmed">31467036</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier A et al. (2015) Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosis--A Pilot Study. PLoS One 10, e0139684. 10.1371/journal.pone.0139684</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0139684</ArticleId><ArticleId IdType="pmc">PMC4596620</ArticleId><ArticleId IdType="pubmed">26444282</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemeth DP and Quan N (2021) Modulation of Neural Networks by Interleukin-1. Brain Plast 7, 17&#x2013;32. 10.3233/BPL-200109</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/BPL-200109</ArticleId><ArticleId IdType="pmc">PMC8461735</ArticleId><ArticleId IdType="pubmed">34631418</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin BS et al. (2014) The adaptor ASC has extracellular and &#x2018;prionoid&#x2019; activities that propagate inflammation. Nat Immunol 15, 727&#x2013;737. 10.1038/ni.2913</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2913</ArticleId><ArticleId IdType="pmc">PMC4116676</ArticleId><ArticleId IdType="pubmed">24952505</ArticleId></ArticleIdList></Reference><Reference><Citation>Baroja-Mazo A et al. (2014) The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol 15, 738&#x2013;748. 10.1038/ni.2919</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2919</ArticleId><ArticleId IdType="pubmed">24952504</ArticleId></ArticleIdList></Reference><Reference><Citation>Venegas C et al. (2017) Microglia-derived ASC specks cross-seed amyloid-beta in Alzheimer&#x2019;s disease. Nature 552, 355&#x2013;361. 10.1038/nature25158</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25158</ArticleId><ArticleId IdType="pubmed">29293211</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassil F et al. (2016) Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proc Natl Acad Sci U S A 113, 9593&#x2013;9598. 10.1073/pnas.1609291113</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1609291113</ArticleId><ArticleId IdType="pmc">PMC5003293</ArticleId><ArticleId IdType="pubmed">27482103</ArticleId></ArticleIdList></Reference><Reference><Citation>Ising C et al. (2019) NLRP3 inflammasome activation drives tau pathology. Nature 575, 669673. 10.1038/s41586-019-1769-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1769-z</ArticleId><ArticleId IdType="pmc">PMC7324015</ArticleId><ArticleId IdType="pubmed">31748742</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi AU et al. (2019) Fragmented mitochondria released from microglia trigger A1 astrocytic response and propagate inflammatory neurodegeneration. Nat Neurosci 22, 1635&#x2013;1648. 10.1038/s41593-019-0486-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0486-0</ArticleId><ArticleId IdType="pmc">PMC6764589</ArticleId><ArticleId IdType="pubmed">31551592</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S et al. (2022) Microglial NLRP3 inflammasome activates neurotoxic astrocytes in depression-like mice. Cell Rep 41, 111532. 10.1016/j.celrep.2022.111532</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111532</ArticleId><ArticleId IdType="pubmed">36288697</ArticleId></ArticleIdList></Reference><Reference><Citation>von Herrmann KM et al. (2020) Slc6a3-dependent expression of a CAPS-associated Nlrp3 allele results in progressive behavioral abnormalities and neuroinflammation in aging mice. J Neuroinflammation 17, 213. 10.1186/s12974-020-01866-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-020-01866-6</ArticleId><ArticleId IdType="pmc">PMC7368774</ArticleId><ArticleId IdType="pubmed">32680528</ArticleId></ArticleIdList></Reference><Reference><Citation>Neel DV et al. (2023) Gasdermin-E mediates mitochondrial damage in axons and neurodegeneration. Neuron. 10.1016/j.neuron.2023.02.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2023.02.019</ArticleId><ArticleId IdType="pmc">PMC10121894</ArticleId><ArticleId IdType="pubmed">36917977</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou WC et al. (2021) AIM2 in regulatory T cells restrains autoimmune diseases. Nature 591, 300&#x2013;305. 10.1038/s41586-021-03231-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03231-w</ArticleId><ArticleId IdType="pmc">PMC8080937</ArticleId><ArticleId IdType="pubmed">33505023</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C et al. (2021) AIM2 controls microglial inflammation to prevent experimental autoimmune encephalomyelitis. J Exp Med 218. 10.1084/jem.20201796</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20201796</ArticleId><ArticleId IdType="pmc">PMC7961553</ArticleId><ArticleId IdType="pubmed">33710283</ArticleId></ArticleIdList></Reference><Reference><Citation>Barclay WE et al. (2022) The AIM2 inflammasome is activated in astrocytes during the late phase of EAE. JCI Insight 7. 10.1172/jci.insight.155563</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.155563</ArticleId><ArticleId IdType="pmc">PMC9089781</ArticleId><ArticleId IdType="pubmed">35451371</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>